TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 18-85 (inclusive) with confirmed diagnosis of OHT or OAG~* Confirmed diagnosis of bilateral OHT or mild to moderate chronic OAG~* Able to undergo washout of all ocular drugs~* An IOP ≥ 24 mmHg at 8:00 AM and ≥ 21 mmHg at 10:00 AM in at least 1 eye; but \< 36 mmHg in both eyes at both Day -5 and Day 1~* Central corneal thickness 500-620 µm at screening and Day -5 in both eyes~* Best corrected visual acuity (BCVA) of +0.7 Log Mar or better~Exclusion Criteria:~* Any history of severe ocular trauma in either eye at any time~* History of angle closure or ocular laser surgery within the past 3 months or any refractive surgery procedure within the past 6 months of Screening Visit in the study eye(s)~* Cataracts that prevent observation or photography of the fundus in either eye

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Experimental Arm 1 (Type: EXPERIMENTAL): ONO-9054 eye drop solution, 30 µg/mL (0.003%), once daily in both eyes, for 28 days.
- Active Comparator Arm 2 (Type: ACTIVE_COMPARATOR): Latanoprost eye drop solution, 0.005%, once daily in both eyes for 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Amiodarone to Prevent Post-Operative Arrhythmias

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* non-emergent coronary artery bypass surgery or valve replacement or repair~* informed consent~Exclusion Criteria:~* any heart rhythm other than sinus~* myocardial infarction within two weeks~* Class IV congestive Heart Failure~* requirement for antiarrhythmic drug therapy~* history of sustained atrial tachyarrhythmias~* treatment with amiodarone within 3 months~* sinus bradycardia (less than 50 bpm) while awake~* advanced conduction system disease~* prolonged QT interval~* clinical hypo- or hyperthyroidism~* women of child bearing potential

- Gender: ALL
- Minimum Age: 0 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sorafenib Maintenance Therapy for Patients With AML After Allogeneic Stem Cell Transplant

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with AML with the FLT3-ITD mutation who have undergone allogeneic HSCT~* Peripheral blood chimerism studies showing \>/= 70% of all cells are of donor origin~* Adequate hematologic and hepatic function~* ECOG performance status 0-2~* Able to swallow whole pills~Exclusion Criteria:~* Evidence of relapsed/recurrent/residual disease as assessed by bone marrow aspirate and biopsy performed between days 30-60 after HSCT~* Active acute graft vs host disease requiring an equivalent dose of \> 0.5 mg/kg/day of prednisone or equivalent or those patients which necessitated the addition of another agent for the treatment of GVHD beyond corticosteroids~* Ongoing uncontrolled infection~* Cardiac disease: congestive heart failure \> class II NYHA, unstable angina or new onset angina (began within the last 3 months) or myocardial infarction within the past 6 months~* Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy~* Uncontrolled hypertension~* Known HIV infection or chronic hepatitis B or C~* Thrombotic or embolic events such as cerebrovascular accident including transient ischemic attacks within the past 6 months~* Pulmonary hemorrhage/bleeding event \> CTCAE v 4.0 Grade 2 within 4 weeks of starting study drug~* Any other hemorrhage/bleeding event \> CTCAE v. 4.0 Grade 3 within 4 weeks of starting study drug~* Serious non-healing wound, non-healing ulcer, or bone fracture~* Evidence or history of bleeding diathesis or coagulopathy~* Major surgery or significant traumatic injury within 4 weeks of starting study drug~* Use of St. John's Wort or rifampin (rifampicin)~* Known or suspected allergy to sorafenib~* Pregnant or breast-feeding~* Receiving any other investigational agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Post-SCT Sorafenib (Type: EXPERIMENTAL): Sorafenib will be given as maintenance therapy after allo HCT to patients with FLT3-ITD AML.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Communities of Healing Mentorship/Support Group Program: Assessment of Preliminary Efficacy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Current or past 6 months AN, BN, or BED~* Recent (within 6 months) discharge from structured treatment~* Involved in outpatient treatment at an appropriate level of care~* Medical stability~* Access to smart phone or computer to complete study assessments~Exclusion Criteria:~* Evidence of needing specialized treatment for another medical or mental health condition

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Peer mentorship (Type: EXPERIMENTAL): Participants meet weekly with an adult peer mentor who has recovered from an eating disorder. The focus of meetings is on eating disorder symptoms and how to overcome them. The goal of this program is to reduce eating disorder symptoms directly by receiving support and guidance from someone who has been through it.
- Social support mentorship (Type: ACTIVE_COMPARATOR): Participants meet weekly with an adult mentor who has not personally struggled with an eating disorder but who is dedicated to offering support. During weekly meetings, participants and mentors (and possibly 1-2 other mentees) engage in activities unrelated to the eating disorder. The goal of this program is to reduce eating disorder symptoms indirectly by exploring aspects of self outside the eating disorder.
- Wait list (Type: NO_INTERVENTION): Participants are on a wait list and then get matched with either type of mentor (of their choice) 6 months later

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Middle Ear Infections in Pediatric Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 6 months to 12 years~* ear tube in the ear which will be treated~* otorrhea for 3 weeks or less~* moderate or severe otorrhea~Exclusion Criteria:~* other ear diseases

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- DF289 (Type: ACTIVE_COMPARATOR): Ear drops
- DF277 (Type: ACTIVE_COMPARATOR): Ear drops
- DF289 plus DF277 (Type: EXPERIMENTAL): Ear drops

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study To Evaluate The Effect Of Single Intravenous Doses Of Tigecycline On QTc Intervals In Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy~* Body mass index 17.5 - 30.5 kg~* Total body weight greater than 50 kg~Exclusion Criteria:~* Recent history of diarrhea~* Use of oral antibiotics in the last 2 weeks~* History of risk factors for QT prolongation pregnant females~* Nursing females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- high dose tigecycline (Type: EXPERIMENTAL): None
- regular dose tigecycline (Type: EXPERIMENTAL): None
- moxifloxacin (Type: ACTIVE_COMPARATOR): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-vascular Endothelial Growth Factor (VEGF) Effects in Patients With neovascuLar Age-related Macular Degeneration (AMD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria~* Newly diagnosed Age-related Macular Degeneration (AMD)~* No previous treatment received for diagnosed AMD~* Visual Acuity 6/7.5 to 6/96~Key Exclusion Criteria:~* standard exclusion criteria for anti-VEGF treatment~* Visual Acuity \<6/96~* nAMD in both eyes, or any condition in other eye which may have required anti- VEGF treatment during study period~* other disease in candidate eye which could have compromised visual acuity or required medical/surgical intervention during study period~* participation to other clinical study with 'not approved' treatment within a year prior to UNRAVEL study participation.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranibizumab (Type: EXPERIMENTAL): 104 patients with an eligible study eye were randomized to be treated with Ranibizumab IVT. 0.5 mg of commercially available Ranibizumab were used for intravitreal injection adminstered by an unblinded injecting physician. 3 injections were performed (Baseline, Month 1, Month 2).
- Aflibercept (Type: ACTIVE_COMPARATOR): 101 patients with an eligible study eye were randomized to be treated with Aflibercept IVT. 2.0 mg of commercially available Aflibercept were used for intravitreal injection admistered by an unblinded injecting physician. 3 injections were performed (Baseline, Month 1, Month 2).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Is HIV-1 positive with plasma Human Immunodeficiency Virus 1 (HIV-1) RNA \<50 copies/mL at screening.~* Has been receiving BIC/FTC/TAF therapy with documented viral suppression (HIV-1 RNA \<50 copies/mL) for ≥3 months prior to signing informed consent and has no history of prior virologic treatment failure on any past or current regimen.~* Female is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: Is not a woman of childbearing potential (WOCBP); is a WOCBP and using an acceptable contraceptive method, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle; a WOCBP must have a negative highly sensitive pregnancy test (\[urine or serum\] as required by local regulations) within 24 hours before the first dose of study intervention; if a urine test cannot be confirmed as negative (e.g. an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.~Exclusion Criteria:~* Has HIV-2 infection.~* Has an active diagnosis of hepatitis due to any cause, including active Hepatitis B Virus (HBV) co-infection.~* Has a history of malignancy ≤5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or cutaneous Kaposi's sarcoma.~* Is taking or is anticipated to require systemic immunosuppressive therapy, immune modulators, or any prohibited therapies.~* Is currently participating in or has participated in a clinical study with an investigational compound or device from 45 days prior to Day 1 through the study treatment period.~* Has a documented or known virologic resistance to DOR.~* Female expects to conceive or donate eggs at any time during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DOR/ISL (Type: EXPERIMENTAL): A fixed dose combination (FDC) of 100 mg doravirine (DOR)/0.75 mg islatravir (ISL) for 144 weeks; and placebo to Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) for 96 weeks.
- BIC/FTC/TAF (Type: ACTIVE_COMPARATOR): 50 mg bictegravir (BIC), 200 mg emtricitabine (FTC), 25 mg tenofovir alafenamide (TAF) for 144 weeks, and placebo to FDC DOR/ISL for 96 weeks. Participants will be offered the option to receive open-label FDC DOR/ISL from Week 144 to Week 156.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Apatinib Combined With Vinorelbine for Non-driver Gene Mutation Non-small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18，Pathologically proven non small cell lung cancer~  * Adenocarcinoma，No-drive gene mutaion (EGFR、ALK、ROS1） by NGS~ * Squamous cell carcinoma，no gene detection~ * Progress after second line~ * PS score \>2~Exclusion Criteria:~* Patients received apatinib or Vinorelbine treatment before~* EGFR, ALK or ROS1 mutation~* Patients with contraindication of chemotherapy~* Pregnant or breast feeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Apatinib Combined With Vinorelbine (Type: EXPERIMENTAL): Apatinib Combined With Vinorelbine Used for Driver Gene Mutation Negative Third-line and Third-line Post Progression Advanced Non-small Cell Lung Cancer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Targeted Naltrexone for Problem Drinkers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female outpatients 18-70 years of age.~* Participants will have an average weekly ethanol consumption of \>=24 standard drinks for men, or \>=18 standard drinks for women (i.e., substantially in excess of non-hazardous drinking levels).~* Participants will be able to read English at the eighth grade or higher level and show no evidence of significant cognitive impairment.~* If a woman of child-bearing potential (i.e., who has not had a hysterectomy, bilateral oophorectomy, tubal ligation or who are less than two years postmenopausal), participant must be non-lactating, practicing a reliable method of birth control, and have a negative serum pregnancy test prior to initiation of treatment.~* Participants will be willing to provide signed, informed consent to participate in the study (including a willingness to reduce drinking to non-hazardous levels).~Exclusion Criteria:~* Participants who have a current, clinically significant physical disease or abnormality on the basis of medical history, physical examination, or routine laboratory evaluation, including total bilirubin elevations of \>110% or ALT or AST elevations \>300% the upper limit of normal or have a diagnosis of Hepatitis B or C infection or AIDS (given the potential for adverse effects of naltrexone on liver function).~* Participants who have a serious psychiatric illness (i.e., schizophrenia, bipolar disorder, severe major depression, panic disorder, borderline personality states, organic mood or mental disorders, or substantial suicide or violence risk) on the basis of history or psychiatric examination.~* Participants who have a current Diagnostic and Statistical Manual of Mental Disorders 4th ed (DSM-IV) diagnosis of drug dependence (other than nicotine dependence) or a lifetime DSM-IV diagnosis of opioid dependence.~* Participants who have a current DSM-IV diagnosis of alcohol dependence that is clinically severe.~* Participants who have used opioids or other psychoactive medications regularly in the month prior to study enrollment.~* Participants who have a history of hypersensitivity to naltrexone.~* Participants who are considered by the investigators to be an unsuitable candidate for receipt of an investigational drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): naltrexone (50 mg orally) for 12-week treatment period
- 2 (Type: PLACEBO_COMPARATOR): placebo for 12-week treatment period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gut Microbiota Transplantation in Systemic Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Fulfillment of the 2013 SSc classification criteria~* Objective GI involvement and provide informed consent.~Exclusion Criteria:~* Severe organ dysfunction (and risk of procedure related complications~* Recent exposure to antibiotics

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ACHIM (Type: ACTIVE_COMPARATOR): Anaerobically Cultivated Human Intestinal Microbiota
- Placebo (Type: PLACEBO_COMPARATOR): Anaerobically Cultivated medium

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* Clinical and ultrasound diagnosis of ADPKD~* Estimated GFR between 15 and 40 ml/min/1.73m2 (by the MDRD 4 variable equation)~* Written informed consent~Exclusion Criteria:~* 24-h Urinary protein excretion rate \>3g (suggestive of a concomitant glomerular disease that could benefit of specific therapy)~* Symptomatic urinary tract lithiasis or obstruction~* Uncontrolled diabetes mellitus (HbA1c \>8%) or hypertension (systolic/diastolic BP \>180/110 mmHg)~* Current urinary tract infection~* Symptomatic biliary tract lithiasis~* Active cancer~* Psychiatric disorders or any condition that might prevent full comprehension of the purposes and risks of the study~* Pregnancy, lactation or child bearing potential and ineffective contraception (estrogen therapy in post menopausal women should not be stopped)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Saline solution. (Type: PLACEBO_COMPARATOR): None
- Octrotide-LAR (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Aerobic Exercise Added to Alprazolam in Panic Disorder Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with panic disorder scored between 20 and 30 by the Hamilton Anxiety Rating Scale/14. (Baseline scale scores were measured during the first interview and diagnoses were made by a psychiatrist using the Structured Clinical Interview for DSM IV).~* Good physical health and normal results determined on a previous physical examination and routine laboratory tests (renal, hepatic, hematological and thyroid function).~* Patients who completed a written informed consent form (which was obtained from every included patient and had been fully explained before the procedure).~Exclusion Criteria:~* A history of some kind of recent somatic disease.~* Diagnosis of some other type of associated or psychiatric disease of axis I of DSM IV, such as affective disorders, drug dependency.~* Hamilton Anxiety Scale lower than 20 points or higher than 30.~* Use of some other type of medication or treatment (including psychotherapy) or having received it during last past 3 months.~* Patients who could not complete the clinical examination~* Patients who have not accepted to complete or sign the written informed consent.~* Pregnant patients or in lactation. (A pregnancy test was performed for women in fertile age)~* Patients with history of rejection to the used drug.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Alprazolam (Type: ACTIVE_COMPARATOR): Patients assigned to the pharmacological plan
- Alprazolam + Aerobic exercise (Type: ACTIVE_COMPARATOR): Patients assigned to mix plan

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete